Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma
{{output}}
Background: Multiple myeloma (MM) is a hematologic cancer withrising incidence worldwide. Autologous stem cell transplantation(ASCT) is a key treatment for eligible patients, but mobilizationfailure remains a major obstacle. Pler... ...
